{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:56:39Z","timestamp":1775094999772,"version":"3.50.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tenosynovial giant cell tumors (TGCTs), a rare benign mesenchymal neoplasm of synovial tissue, often incurs chronic pain, joint destruction and repeated surgery, markedly impairing quality of life. Historically, surgery was the only effective option. The colony-stimulating factor 1 receptor (CSF1R) inhibitor pexidartinib broke this therapeutic deadlock, pioneering systemic therapy and shaping subsequent drug development. Further exploration of pexidartinib and associated clinical studies in the field of TGCT have continued following its approval, with updated data and outcomes continuing to play a crucial role in guiding the clinical application of pexidartinib for treatment of TGCT. This review provides a comprehensive summary of the preclinical and clinical development of pexidartinib for treatment of TGCT, and highlights the recent updates in clinical studies and findings since its approval. These include long-term efficacy, optimization of therapeutic strategies, management of risks associated with long-term use, and real-world patient-reported outcomes, all of importance and value for patients and physicians in clinical practice. Here we aim to provide guidance for the improved clinical application of this drug class to enhance patient benefits in TGCT treatment.<\/jats:p>","DOI":"10.1007\/s10555-026-10328-z","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:40:17Z","timestamp":1775094017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors"],"prefix":"10.1007","volume":"45","author":[{"given":"Yulin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoer","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"10328_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102491","volume":"112","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti, S., D\u00fcrr, H. R., Schaefer, I. M., Woertler, K., Haas, R., Trama, A., et al. (2023). Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. Cancer Treatment Reviews, 112, Article 102491. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102491","journal-title":"Cancer Treatment Reviews"},{"issue":"4","key":"10328_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn, H. L., Tong, S., McQuarrie, K., Vernon, C., Hanlon, J., Maclaine, G., et al. (2016). Patient-reported symptoms of tenosynovial giant cell tumors. Clinical Therapeutics, 38(4), 778\u2013793. https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.008","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10328_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13921-7","volume":"25","author":"C Scheele","year":"2025","unstructured":"Scheele, C., Harrasser, N., Beischl, S., Dammerer, D., Lenze, U., Knebel, C., et al. (2025). Tenosynovial giant cell tumours of the foot and ankle: A retrospective single centre experience with surgical treatment of 34 cases. BMC Cancer, 25(1), Article 530.","journal-title":"BMC Cancer"},{"issue":"18","key":"10328_CR4","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1080\/14796694.2025.2520744","volume":"21","author":"M van de Sande","year":"2025","unstructured":"van de Sande, M., Blay, J. Y., Tap, W., Lee, M., Kaiser, E., Beaver, S., et al. (2025). The economic and humanistic burden of tenosynovial giant cell tumor: A targeted literature review. Future Oncology, 21(18), 2385\u20132400. https:\/\/doi.org\/10.1080\/14796694.2025.2520744","journal-title":"Future Oncology"},{"key":"10328_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104951","volume":"216","author":"H Xu","year":"2025","unstructured":"Xu, H., Li, Y., Lin, N., Ye, Z., & Niu, X. (2025). Tenosynovial giant cell tumor (TGCT): Mechanisms and advances in targeted treatments. Critical Reviews in Oncology\/Hematology, 216, Article 104951. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104951","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"10328_CR6","doi-asserted-by":"publisher","DOI":"10.2196\/ijmr.9325","volume":"7","author":"MJ Mastboom","year":"2018","unstructured":"Mastboom, M. J., Planje, R., & van de Sande, M. A. (2018). The patient perspective on the impact of tenosynovial giant cell tumors on daily living: Crowdsourcing study on physical function and quality of life. Interactive Journal of Medical Research, 7(1), Article e4. https:\/\/doi.org\/10.2196\/ijmr.9325","journal-title":"Interactive Journal of Medical Research"},{"issue":"6","key":"10328_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","volume":"88","author":"MJL Mastboom","year":"2017","unstructured":"Mastboom, M. J. L., Verspoor, F. G. M., Verschoor, A. J., Uittenbogaard, D., Nemeth, B., Mastboom, W. J. B., et al. (2017). Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthopaedica, 88(6), 688\u2013694. https:\/\/doi.org\/10.1080\/17453674.2017.1361126","journal-title":"Acta Orthopaedica"},{"issue":"3","key":"10328_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121451","volume":"10","author":"GP Xie","year":"2015","unstructured":"Xie, G. P., Jiang, N., Liang, C. X., Zeng, J. C., Chen, Z. Y., Xu, Q., et al. (2015). Pigmented villonodular synovitis: A retrospective multicenter study of 237 cases. PLoS ONE, 10(3), Article e0121451. https:\/\/doi.org\/10.1371\/journal.pone.0121451","journal-title":"PLoS ONE"},{"issue":"6","key":"10328_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.semarthrit.2010.07.005","volume":"40","author":"S Ottaviani","year":"2011","unstructured":"Ottaviani, S., Ayral, X., Dougados, M., & Gossec, L. (2011). Pigmented villonodular synovitis: A retrospective single-center study of 122 cases and review of the literature. Seminars in Arthritis and Rheumatism, 40(6), 539\u2013546. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.07.005","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"4","key":"10328_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.clinthera.2018.03.001","volume":"40","author":"TM Burton","year":"2018","unstructured":"Burton, T. M., Ye, X., Parker, E. D., Bancroft, T., & Healey, J. (2018). Burden of illness associated with tenosynovial giant cell tumors. Clinical Therapeutics, 40(4), 593-602.e591. https:\/\/doi.org\/10.1016\/j.clinthera.2018.03.001","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10328_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01883-5","volume":"16","author":"J Lopez-Bastida","year":"2021","unstructured":"Lopez-Bastida, J., Aranda-Reneo, I., Rodr\u00edguez-S\u00e1nchez, B., Pe\u00f1a-Longobardo, L. M., Ye, X., Laeis, P., et al. (2021). Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: An observational disease registry. Orphanet Journal of Rare Diseases, 16(1), Article 294. https:\/\/doi.org\/10.1186\/s13023-021-01883-5","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10328_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01820-6","volume":"16","author":"NM Bernthal","year":"2021","unstructured":"Bernthal, N. M., Spierenburg, G., Healey, J. H., Palmerini, E., Bauer, S., Gelderblom, H., et al. (2021). The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: A prospective multicenter study. Orphanet Journal of Rare Diseases, 16(1), Article 191. https:\/\/doi.org\/10.1186\/s13023-021-01820-6","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"10","key":"10328_CR13","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3899\/jrheum.160816","volume":"44","author":"V Ehrenstein","year":"2017","unstructured":"Ehrenstein, V., Andersen, S. L., Qazi, I., Sankar, N., Pedersen, A. B., Sikorski, R., et al. (2017). Tenosynovial giant cell tumor: Incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. The Journal of Rheumatology, 44(10), 1476\u20131483. https:\/\/doi.org\/10.3899\/jrheum.160816","journal-title":"The Journal of Rheumatology"},{"key":"10328_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/ott.S345878","volume":"15","author":"A Vaynrub","year":"2022","unstructured":"Vaynrub, A., Healey, J. H., Tap, W., & Vaynrub, M. (2022). Pexidartinib in the management of advanced tenosynovial giant cell tumor: Focus on patient selection and special considerations. OncoTargets and Therapy, 15, 53\u201366. https:\/\/doi.org\/10.2147\/ott.S345878","journal-title":"OncoTargets and Therapy"},{"issue":"6","key":"10328_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/14737140.2020.1757441","volume":"20","author":"E Palmerini","year":"2020","unstructured":"Palmerini, E., Longhi, A., Donati, D. M., & Staals, E. L. (2020). Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: Safety and efficacy. Expert Review of Anticancer Therapy, 20(6), 441\u2013445. https:\/\/doi.org\/10.1080\/14737140.2020.1757441","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"2","key":"10328_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","volume":"51","author":"E Palmerini","year":"2015","unstructured":"Palmerini, E., Staals, E. L., Maki, R. G., Pengo, S., Cioffi, A., Gambarotti, M., et al. (2015). Tenosynovial giant cell tumour\/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. European Journal of Cancer, 51(2), 210\u2013217. https:\/\/doi.org\/10.1016\/j.ejca.2014.11.001","journal-title":"European Journal of Cancer"},{"key":"10328_CR17","doi-asserted-by":"publisher","unstructured":"van der Heijden, L., Mastboom, M. J., Dijkstra, P. D., & van de Sande, M. A. (2014). Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: A retrospective analysis of 30 patients. Bone & Joint Journal, 96-B(8), 1111\u20131118. https:\/\/doi.org\/10.1302\/0301-620x.96b8.33608","DOI":"10.1302\/0301-620x.96b8.33608"},{"issue":"11","key":"10328_CR18","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOSGlobal-D-20-00028","volume":"4","author":"JH Healey","year":"2020","unstructured":"Healey, J. H., Bernthal, N. M., & van de Sande, M. (2020). Management of tenosynovial giant cell tumor: A neoplastic and inflammatory disease. JAAOS Global Research & Reviews, 4(11), Article e20.00028. https:\/\/doi.org\/10.5435\/JAAOSGlobal-D-20-00028","journal-title":"JAAOS Global Research & Reviews"},{"key":"10328_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1523979","volume":"15","author":"P Gao","year":"2025","unstructured":"Gao, P., Ji, S. C., Liang, W., Bai, G. J., Ren, J. J., Zhong, F. L., et al. (2025). Knowledge map of recurrence in tenosynovial giant cell tumor: A bibliometric analysis. Frontiers in Oncology, 15, Article 1523979. https:\/\/doi.org\/10.3389\/fonc.2025.1523979","journal-title":"Frontiers in Oncology"},{"key":"10328_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1331815","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang, T., Zeng, B., Liu, K., Zeng, Q., Wang, N., Peng, L., et al. (2024). Exploration of the molecular biological mechanisms and review of postoperative radiotherapy cases in tenosynovial giant cell tumors. Frontiers in Oncology, 14, Article 1331815. https:\/\/doi.org\/10.3389\/fonc.2024.1331815","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10328_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61060949","volume":"61","author":"T Cengiz","year":"2025","unstructured":"Cengiz, T., Ayd\u0131n \u015eim\u015fek, \u015e, Bayar, E., Erdo\u011fan, F., Yurtbay, A., Co\u015fkun, H. S., et al. (2025). Tenosynovial giant cell tumors of the hand: Analysis of risk factors for surgical margin and recurrence. Medicina (Kaunas, Lithuania), 61(6), Article 949. https:\/\/doi.org\/10.3390\/medicina61060949","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"5","key":"10328_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1053\/jars.2001.24068","volume":"17","author":"CE Blanco","year":"2001","unstructured":"Blanco, C. E., Leon, H. O., & Guthrie, T. B. (2001). Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee. Arthroscopy, 17(5), 527\u2013531. https:\/\/doi.org\/10.1053\/jars.2001.24068","journal-title":"Arthroscopy"},{"issue":"1","key":"10328_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijrobp.2008.10.058","volume":"75","author":"M Horoschak","year":"2009","unstructured":"Horoschak, M., Tran, P. T., Bachireddy, P., West, R. B., Mohler, D., Beaulieu, C. F., et al. (2009). External beam radiation therapy enhances local control in pigmented villonodular synovitis. International Journal of Radiation Oncology, Biology, Physics, 75(1), 183\u2013187. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.058","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"19","key":"10328_CR24","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1002\/cncr.26529","volume":"118","author":"AM Griffin","year":"2012","unstructured":"Griffin, A. M., Ferguson, P. C., Catton, C. N., Chung, P. W., White, L. M., Wunder, J. S., et al. (2012). Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor\/pigmented villonodular synovitis with radiotherapy and surgery. Cancer, 118(19), 4901\u20134909. https:\/\/doi.org\/10.1002\/cncr.26529","journal-title":"Cancer"},{"issue":"9","key":"10328_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.arthro.2012.02.007","volume":"28","author":"LH de Carvalho","year":"2012","unstructured":"de Carvalho, L. H., Jr., Soares, L. F., Gon\u00e7alves, M. B., Temponi, E. F., & de Melo Silva, O., Jr. (2012). Long-term success in the treatment of diffuse pigmented villonodular synovitis of the knee with subtotal synovectomy and radiotherapy. Arthroscopy, 28(9), 1271\u20131274. https:\/\/doi.org\/10.1016\/j.arthro.2012.02.007","journal-title":"Arthroscopy"},{"issue":"28","key":"10328_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000026659","volume":"100","author":"X Xiang","year":"2021","unstructured":"Xiang, X., Jiang, W., Qiu, C., Xiao, N., & Liang, J. (2021). Image-guided, intensity-modulated radiotherapy for the treatment of diffuse-type tenosynovial giant cell tumor of the knee: Case report and review of the literature. Medicine, 100(28), Article e26659. https:\/\/doi.org\/10.1097\/md.0000000000026659","journal-title":"Medicine"},{"issue":"3","key":"10328_CR27","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/j.prro.2022.11.004","volume":"13","author":"C Baniel","year":"2023","unstructured":"Baniel, C., Yoo, C. H., Jiang, A., von Eyben, R., Mohler, D. G., Ganjoo, K., et al. (2023). Long-term outcomes of diffuse or recurrent tenosynovial giant cell tumor treated with postoperative external beam radiation therapy. Practical Radiation Oncology, 13(3), e301\u2013e307. https:\/\/doi.org\/10.1016\/j.prro.2022.11.004","journal-title":"Practical Radiation Oncology"},{"issue":"3","key":"10328_CR28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West, R. B., Rubin, B. P., Miller, M. A., Subramanian, S., Kaygusuz, G., Montgomery, K., et al. (2006). A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proceedings of the National Academy of Sciences, 103(3), 690\u2013695. https:\/\/doi.org\/10.1073\/pnas.0507321103","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"10328_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/gcc.22807","volume":"59","author":"J Ho","year":"2020","unstructured":"Ho, J., Peters, T., Dickson, B. C., Swanson, D., Fernandez, A., Frova-Seguin, A., et al. (2020). Detection of CSF1 rearrangements deleting the 3\u2019 UTR in tenosynovial giant cell tumors. Genes, Chromosomes & Cancer, 59(2), 96\u2013105. https:\/\/doi.org\/10.1002\/gcc.22807","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"1","key":"10328_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/gcc.20501","volume":"47","author":"E M\u00f6ller","year":"2008","unstructured":"M\u00f6ller, E., Mandahl, N., Mertens, F., & Panagopoulos, I. (2008). Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes, Chromosomes & Cancer, 47(1), 21\u201325. https:\/\/doi.org\/10.1002\/gcc.20501","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"2","key":"10328_CR31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/his.13744","volume":"74","author":"MJL Mastboom","year":"2019","unstructured":"Mastboom, M. J. L., Hoek, D. M., Bov\u00e9e, J., van de Sande, M. A. J., & Szuhai, K. (2019). Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee? Histopathology, 74(2), 332\u2013340. https:\/\/doi.org\/10.1111\/his.13744","journal-title":"Histopathology"},{"issue":"6","key":"10328_CR32","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","volume":"31","author":"JS Cupp","year":"2007","unstructured":"Cupp, J. S., Miller, M. A., Montgomery, K. D., Nielsen, T. O., O\u2019Connell, J. X., Huntsman, D., et al. (2007). Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. The American Journal of Surgical Pathology, 31(6), 970\u2013976. https:\/\/doi.org\/10.1097\/PAS.0b013e31802b86f8","journal-title":"The American Journal of Surgical Pathology"},{"issue":"12","key":"10328_CR33","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1002\/ijc.32421","volume":"145","author":"Y Tsuda","year":"2019","unstructured":"Tsuda, Y., Hirata, M., Katayama, K., Motoi, T., Matsubara, D., Oda, Y., et al. (2019). Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations. International Journal of Cancer, 145(12), 3276\u20133284. https:\/\/doi.org\/10.1002\/ijc.32421","journal-title":"International Journal of Cancer"},{"key":"10328_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1012527","volume":"12","author":"T Gauduchon","year":"2022","unstructured":"Gauduchon, T., Vanacker, H., Pissaloux, D., Cassier, P., Dufresne, A., Karanian, M., et al. (2022). Expanding the molecular spectrum of tenosynovial giant cell tumors. Frontiers in Oncology, 12, Article 1012527. https:\/\/doi.org\/10.3389\/fonc.2022.1012527","journal-title":"Frontiers in Oncology"},{"key":"10328_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820046","volume":"13","author":"M Robert","year":"2022","unstructured":"Robert, M., Farese, H., & Miossec, P. (2022). Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features. Frontiers in Immunology, 13, Article 820046. https:\/\/doi.org\/10.3389\/fimmu.2022.820046","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10328_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3233\/tub-220005","volume":"44","author":"WD Tap","year":"2022","unstructured":"Tap, W. D., & Healey, J. H. (2022). Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor. Tumor Biology, 44(1), 239\u2013248. https:\/\/doi.org\/10.3233\/tub-220005","journal-title":"Tumor Biology"},{"issue":"4","key":"10328_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/14728222.2022.2067040","volume":"26","author":"G Spierenburg","year":"2022","unstructured":"Spierenburg, G., van der Heijden, L., van Langevelde, K., Szuhai, K., Bov\u00e9e, J., van de Sande, M. A. J., et al. (2022). Tenosynovial giant cell tumors (TGCT): Molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opinion on Therapeutic Targets, 26(4), 333\u2013345. https:\/\/doi.org\/10.1080\/14728222.2022.2067040","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"10197","key":"10328_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/s0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap, W. D., Gelderblom, H., Palmerini, E., Desai, J., Bauer, S., Blay, J. Y., et al. (2019). Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial. Lancet, 394(10197), 478\u2013487. https:\/\/doi.org\/10.1016\/s0140-6736(19)30764-0","journal-title":"Lancet"},{"issue":"16","key":"10328_CR39","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb, Y. N. (2019). Pexidartinib: First approval. Drugs, 79(16), 1805\u20131812. https:\/\/doi.org\/10.1007\/s40265-019-01210-0","journal-title":"Drugs"},{"key":"10328_CR40","doi-asserted-by":"publisher","unstructured":"Monestime, S., & Lazaridis, D. (2020). Pexidartinib (TURALIO\u2122): The first FDA-indicated systemic treatment for tenosynovial giant cell tumor. Drugs R & D, 20(3), 189\u2013195. https:\/\/doi.org\/10.1007\/s40268-020-00314-3","DOI":"10.1007\/s40268-020-00314-3"},{"key":"10328_CR41","unstructured":"US FDA (2019). Prescribing guidelines for pexidartinib. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211810s000lbl.pdf. Accessed 1 Feb 2026."},{"issue":"7","key":"10328_CR42","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-025-02191-z","volume":"85","author":"A Lee","year":"2025","unstructured":"Lee, A. (2025). Vimseltinib: First approval. Drugs, 85(7), 985\u2013989. https:\/\/doi.org\/10.1007\/s40265-025-02191-z","journal-title":"Drugs"},{"key":"10328_CR43","unstructured":"US FDA (2025). Prescribing guidelines for vimseltinib. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219304s000lbl.pdf. Accessed 1 Feb 2026."},{"key":"10328_CR44","unstructured":"Taiwan Food and Drug Administration (2023). TURALIO (pexidartinib) capsules 200 mg. https:\/\/www.fda.gov.tw\/eng\/searchin.aspx?q=pexidartinib. Accessed 1 Feb 2026."},{"key":"10328_CR45","unstructured":"Ministry of Food and Drug Safety of The Republic of Korea (2021). TURALIO\u00ae capsules 200 milligrams (pexidartinib HCl). https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetailCache?cacheSeq=202108140aupdateTs2025-02-18%2015:24:07.832821b. Accessed 1 Feb 2026."},{"key":"10328_CR46","unstructured":"ClinicalTrials.gov (2020). A Study of the efficacy and safety of pexidartinib in adult subjects with TGCT (PLX3397). https:\/\/clinicaltrials.gov\/study\/NCT04488822?term=TGCT&intr=pexidartinib&rank=3. Accessed 1 Dec 2024."},{"key":"10328_CR47","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2147\/dddt.S253232","volume":"14","author":"B Benner","year":"2020","unstructured":"Benner, B., Good, L., Quiroga, D., Schultz, T. E., Kassem, M., Carson, W. E., et al. (2020). Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: A systematic review of pre-clinical and clinical development. Drug Design, Development and Therapy, 14, 1693\u20131704. https:\/\/doi.org\/10.2147\/dddt.S253232","journal-title":"Drug Design, Development and Therapy"},{"issue":"29","key":"10328_CR48","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2217\/fon-2020-0542","volume":"16","author":"H Gelderblom","year":"2020","unstructured":"Gelderblom, H., & de San, M. V. (2020). Pexidartinib: First approved systemic therapy for patients with tenosynovial giant cell tumor. Future Oncology, 16(29), 2345\u20132356. https:\/\/doi.org\/10.2217\/fon-2020-0542","journal-title":"Future Oncology"},{"issue":"12","key":"10328_CR49","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.2174\/1871520620999201102123555","volume":"21","author":"Y Alsayadi","year":"2021","unstructured":"Alsayadi, Y., & Chawla, P. A. (2021). Prospects of treating tenosynovial giant cell tumor through pexidartinib: A review. Anti-Cancer Agents in Medicinal Chemistry, 21(12), 1510\u20131519. https:\/\/doi.org\/10.2174\/1871520620999201102123555","journal-title":"Anti-Cancer Agents in Medicinal Chemistry"},{"issue":"6","key":"10328_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/17512433.2020.1771179","volume":"13","author":"GG Baldi","year":"2020","unstructured":"Baldi, G. G., Gronchi, A., & Stacchiotti, S. (2020). Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. Expert Review of Clinical Pharmacology, 13(6), 571\u2013576. https:\/\/doi.org\/10.1080\/17512433.2020.1771179","journal-title":"Expert Review of Clinical Pharmacology"},{"issue":"5","key":"10328_CR51","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., et al. (2015). Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. New England Journal of Medicine, 373(5), 428\u2013437. https:\/\/doi.org\/10.1056\/NEJMoa1411366","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10328_CR52","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s13577-022-00823-0","volume":"36","author":"S Thongchot","year":"2023","unstructured":"Thongchot, S., Duangkaew, S., Yotchai, W., Maungsomboon, S., Phimolsarnti, R., Asavamongkolkul, A., et al. (2023). Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis. Human Cell, 36(1), 456\u2013467. https:\/\/doi.org\/10.1007\/s13577-022-00823-0","journal-title":"Human Cell"},{"issue":"8","key":"10328_CR53","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1535-7163.Mct-20-0591","volume":"20","author":"T Fujiwara","year":"2021","unstructured":"Fujiwara, T., Yakoub, M. A., Chandler, A., Christ, A. B., Yang, G., Ouerfelli, O., et al. (2021). CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Molecular Cancer Therapeutics, 20(8), 1388\u20131399. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0591","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2","key":"10328_CR54","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.Ccr-21-2007","volume":"28","author":"WD Tap","year":"2022","unstructured":"Tap, W. D., Singh, A. S., Anthony, S. P., Sterba, M., Zhang, C., Healey, J. H., et al. (2022). Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. Clinical Cancer Research, 28(2), 298\u2013307. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-2007","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10328_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., et al. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10328_CR56","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/jcph.1753","volume":"61","author":"O Yin","year":"2021","unstructured":"Yin, O., Wagner, A. J., Kang, J., Knebel, W., Zahir, H., van de Sande, M., et al. (2021). Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. Journal of Clinical Pharmacology, 61(4), 480\u2013492. https:\/\/doi.org\/10.1002\/jcph.1753","journal-title":"Journal of Clinical Pharmacology"},{"key":"10328_CR57","unstructured":"US FDA (2025). Prescribing guidelines for pexidartinib. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211810s013lbl.pdf. Accessed 1 Feb 2026."},{"issue":"4","key":"10328_CR58","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40487-025-00365-z","volume":"13","author":"H Xu","year":"2025","unstructured":"Xu, H., Wu, P., Ye, Z., Fan, Z., Li, T., Chen, T. W., et al. (2025). A phase 3 study of the efficacy and safety of pexidartinib in East Asian patients with tenosynovial giant cell tumor. Oncology Therapy, 13(4), 1025\u20131039. https:\/\/doi.org\/10.1007\/s40487-025-00365-z","journal-title":"Oncology Therapy"},{"issue":"1","key":"10328_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02926-9","volume":"18","author":"C McCabe","year":"2023","unstructured":"McCabe, C., Wright, H., Polson, K., & Wagner, A. J. (2023). Supporting patients in the transition to the revised pexidartinib dosing regimen: Perspectives from the multidisciplinary clinical and allied health professional team. Orphanet Journal of Rare Diseases, 18(1), Article 313. https:\/\/doi.org\/10.1186\/s13023-023-02926-9","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"7","key":"10328_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae345","volume":"30","author":"AJ Wagner","year":"2025","unstructured":"Wagner, A. J., Tap, W. D., Bauer, S., Blay, J. Y., Desai, J., Gelderblom, H., et al. (2025). Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: Final results of the ENLIVEN study. The Oncologist, 30(7), Article oyae345. https:\/\/doi.org\/10.1093\/oncolo\/oyae345","journal-title":"The Oncologist"},{"key":"10328_CR61","unstructured":"Desai, J., Stacchiotti, S., Tap, W. D., Inoue, S., Qian, M., Rajper, A., et al. (2024). Tumor response and regrowth in relation to clinical events among pexidartinib-treated patients in the phase 3 ENLIVEN trial. In Connective Tissue Oncology Society (CTOS) Annual Meeting, San Diego, CA, USA, November 13\u201316. https:\/\/ctos2024.eventscribe.net\/fsPopup.asp?PosterID=691303&mode=posterInfo. Accessed Mar 2026."},{"issue":"6","key":"10328_CR62","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.33312","volume":"127","author":"H Gelderblom","year":"2021","unstructured":"Gelderblom, H., Wagner, A. J., Tap, W. D., Palmerini, E., Wainberg, Z. A., Desai, J., et al. (2021). Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer, 127(6), 884\u2013893. https:\/\/doi.org\/10.1002\/cncr.33312","journal-title":"Cancer"},{"issue":"1","key":"10328_CR63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/corr.0000000000002335","volume":"481","author":"JH Healey","year":"2023","unstructured":"Healey, J. H., Tap, W. D., Gelhorn, H. L., Ye, X., Speck, R. M., Palmerini, E., et al. (2023). Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: Results from ENLIVEN. Clinical Orthopaedics and Related Research, 481(1), 107\u2013116. https:\/\/doi.org\/10.1097\/corr.0000000000002335","journal-title":"Clinical Orthopaedics and Related Research"},{"issue":"2","key":"10328_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar, J. T., Young, J. P., Jr., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain, 94(2), 149\u2013158. https:\/\/doi.org\/10.1016\/s0304-3959(01)00349-9","journal-title":"Pain"},{"issue":"4","key":"10328_CR65","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1093\/oncolo\/oyad282","volume":"29","author":"F Lin","year":"2024","unstructured":"Lin, F., Kwong, W. J., Pan, I., Ye, X., Dai, D., & Tap, W. (2024). Real-world patient experience of pexidartinib for tenosynovial giant-cell tumor. The Oncologist, 29(4), e535\u2013e543. https:\/\/doi.org\/10.1093\/oncolo\/oyad282","journal-title":"The Oncologist"},{"issue":"6","key":"10328_CR66","doi-asserted-by":"publisher","first-page":"S390","DOI":"10.1016\/j.jval.2024.03.2467","volume":"27","author":"D Dai","year":"2024","unstructured":"Dai, D., Tecson, K., Pan, I., Ye, X., & Tap, W. D. (2024). RWD170 real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor. Value in Health, 27(6), S390\u2013S391. https:\/\/doi.org\/10.1016\/j.jval.2024.03.2467","journal-title":"Value in Health"},{"key":"10328_CR67","unstructured":"Dai, D., Lin, F., Pan, I., Freivogel, K., Ye, X., Tecson, K., et al. (2023). 1537419 Patient-reported continued benefits in patients treated with pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United States. In Connective Tissue Oncology Society (CTOS) annual meeting,\u00a0Dublin, Ireland, November 1\u20134.\u00a0https:\/\/ctos2023.eventscribe.net\/fsPopup.asp?PosterID=604332&mode=posterInfo. Accessed 1 Mar 2026."},{"issue":"5","key":"10328_CR68","doi-asserted-by":"publisher","first-page":"e863","DOI":"10.1002\/onco.13629","volume":"26","author":"JH Lewis","year":"2021","unstructured":"Lewis, J. H., Gelderblom, H., van de Sande, M., Stacchiotti, S., Healey, J. H., Tap, W. D., et al. (2021). Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors. The Oncologist, 26(5), e863\u2013e873. https:\/\/doi.org\/10.1002\/onco.13629","journal-title":"The Oncologist"},{"issue":"1","key":"10328_CR69","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajpath.2011.03.029","volume":"179","author":"ZA Radi","year":"2011","unstructured":"Radi, Z. A., Koza-Taylor, P. H., Bell, R. R., Obert, L. A., Runnels, H. A., Beebe, J. S., et al. (2011). Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. American Journal of Pathology, 179(1), 240\u2013247. https:\/\/doi.org\/10.1016\/j.ajpath.2011.03.029","journal-title":"American Journal of Pathology"},{"issue":"1","key":"10328_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A. M., Ries, C. H., & R\u00fcttinger, D. (2017). Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy of Cancer, 5(1), Article 53.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"13","key":"10328_CR71","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2217\/fon-2021-1475","volume":"18","author":"C Dharmani","year":"2022","unstructured":"Dharmani, C., Wang, E., Salas, M., McCabe, C., Diggs, A., Choi, Y., et al. (2022). Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: Framework and experience. Future Oncology, 18(13), 1595\u20131607. https:\/\/doi.org\/10.2217\/fon-2021-1475","journal-title":"Future Oncology"},{"issue":"33","key":"10328_CR72","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1080\/14796694.2024.2373687","volume":"20","author":"C Dharmani","year":"2024","unstructured":"Dharmani, C., Fofah, O., Fallon, M., Rajper, A. W., Wooddell, M., & Salas, M. (2024). TURALIO\u00ae risk evaluation and mitigation strategy program (tREMS): 3-year retrospective hepatic safety assessment. Future Oncology, 20(33), 2559\u20132564. https:\/\/doi.org\/10.1080\/14796694.2024.2373687","journal-title":"Future Oncology"},{"issue":"15","key":"10328_CR73","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1080\/14796694.2025.2509409","volume":"21","author":"A Waheed Rajper","year":"2025","unstructured":"Waheed Rajper, A., Charles, D., Lalitha, C., Oluwatosin, F., & Wooddell, M. J. (2025). TURALIO\u00ae risk evaluation and mitigation strategy (tREMS) program: 5-year retrospective hepatic safety assessment. Future Oncology, 21(15), 1859\u20131865. https:\/\/doi.org\/10.1080\/14796694.2025.2509409","journal-title":"Future Oncology"},{"key":"10328_CR74","unstructured":"ClinicalTrials.gov (2021). A long-term study evaluating hepatotoxicity associated With TURALIO\u2122 (Pexidartinib) treatment. https:\/\/clinicaltrials.gov\/study\/NCT04635111?term=TGCT&intr=pexidartinib&rank=4. Accessed 1 Dec 2024."},{"issue":"1","key":"10328_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35634","volume":"131","author":"J Desai","year":"2024","unstructured":"Desai, J., Wagner, A. J., Garcia, I. C., Cesari, M., Gordon, M., Lin, C. C., et al. (2024). A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib. Cancer, 131(1), Article e35634. https:\/\/doi.org\/10.1002\/cncr.35634","journal-title":"Cancer"},{"key":"10328_CR76","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7768764","volume":"2022","author":"NM Bernthal","year":"2022","unstructured":"Bernthal, N. M., Randall, R. L., Zeitlinger, L. N., Geiger, E. J., & Healey, J. H. (2022). Complementary effects of surgery and pexidartinib in the management of patients with complex diffuse-tenosynovial giant cell tumor. Case Reports in Orthopedics, 2022, Article 7768764. https:\/\/doi.org\/10.1155\/2022\/7768764","journal-title":"Case Reports in Orthopedics"},{"issue":"1","key":"10328_CR77","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jos.2022.10.016","volume":"29","author":"EJ Geiger","year":"2024","unstructured":"Geiger, E. J., Jensen, A. R., Singh, A. S., Nelson, S. D., & Bernthal, N. M. (2024). Use of neoadjuvant pexidartinib with limb salvage surgery for diffuse tenosynovial giant cell tumor: A case report. Journal of Orthopaedic Science, 29(1), 458\u2013462. https:\/\/doi.org\/10.1016\/j.jos.2022.10.016","journal-title":"Journal of Orthopaedic Science"},{"issue":"4","key":"10328_CR78","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40487-024-00298-z","volume":"12","author":"E Palmerini","year":"2024","unstructured":"Palmerini, E., Peta, G., & Tuzzato, G. (2024). Pexidartinib upfront in a case of tenosynovial giant cell tumor: Proof of concept for a treatment paradigm shift. Oncology Therapy, 12(4), 833\u2013841. https:\/\/doi.org\/10.1007\/s40487-024-00298-z","journal-title":"Oncology Therapy"},{"key":"10328_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-018-0101-2","volume":"8","author":"N Giustini","year":"2018","unstructured":"Giustini, N., Bernthal, N. M., Bukata, S. V., & Singh, A. S. (2018). Tenosynovial giant cell tumor: Case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clinical Sarcoma Research, 8, Article 14. https:\/\/doi.org\/10.1186\/s13569-018-0101-2","journal-title":"Clinical Sarcoma Research"},{"key":"10328_CR80","unstructured":"Healey, J. H., Wagner, A. J., Stacchiotti, S., Qian, M., Tecson, K., Wooddell, M., et al. (2024). Pexidartinib use in patients with tenosynovial giant cell tumor: An analysis of the phase 3 randomized ENLIVEN clinical trial according to surgical history. In Connective Tissue Oncology Society (CTOS) annual meeting, San Diego, CA, USA, November\u00a013\u201316. https:\/\/ctos2024.eventscribe.net\/fsPopup.asp?PresentationID=1491244&mode=presInfo. Accessed 1 Mar 2026."},{"issue":"9","key":"10328_CR81","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s11999.0000000000000102","volume":"476","author":"MJL Mastboom","year":"2018","unstructured":"Mastboom, M. J. L., Verspoor, F. G. M., Uittenbogaard, D., Schaap, G. R., Jutte, P. C., Schreuder, H. W. B., et al. (2018). Tenosynovial giant cell tumors in children: A similar entity compared with adults. Clinical Orthopaedics and Related Research, 476(9), 1803\u20131812. https:\/\/doi.org\/10.1007\/s11999.0000000000000102","journal-title":"Clinical Orthopaedics and Related Research"},{"key":"10328_CR82","unstructured":"Lake, J. A., Akshintala, S., Derdak, J., Thomas, E., Brems, J., Hurtt, J., et al. (2024) Tenosynovial giant cell tumor in children: Interim results from a phase 1 study of pexidartinib (Turalio\u00ae). In Connective Tissue Oncology Society (CTOS) annual meeting, San Diego, CA, USA, November 13\u201316. https:\/\/ctos2024.eventscribe.net\/fsPopup.asp?efp=QUJLTFhUVUoyMjc5MQ&PosterID=691270&rnd=0.4013743&mode=posterInfo. Accessed 1 Mar 2026."},{"issue":"1","key":"10328_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-026-04231-7","volume":"21","author":"S Stern","year":"2026","unstructured":"Stern, S., McKenzie, P. F., Baldi, G. G., Scharschmidt, T. J., Palmerini, E., & Rothschild, S. (2026). Pediatric patients with tenosynovial giant cell tumor: Real-world evidence from an observational registry. Orphanet Journal of Rare Diseases, 21(1), Article 68. https:\/\/doi.org\/10.1186\/s13023-026-04231-7","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"4","key":"10328_CR84","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/futurepharmacol3040056","volume":"3","author":"A Stamatiou","year":"2023","unstructured":"Stamatiou, A., Nguyen-Ngoc, T., Wetterwald, L., Dolcan, A.-M., Dei Tos, G., Cherix, S., et al. (2023). Overview of pharmacological therapies for diffuse tenosynovial giant cell tumor. Future Pharmacology, 3(4), 926\u2013937. https:\/\/doi.org\/10.3390\/futurepharmacol3040056","journal-title":"Future Pharmacology"},{"issue":"4","key":"10328_CR85","doi-asserted-by":"publisher","first-page":"307","DOI":"10.56875\/2589-0646.1032","volume":"16","author":"AS Chan","year":"2023","unstructured":"Chan, A. S., Katiyar, V., Dy, P., & Singh, V. (2023). Updates on the treatment of tenosynovial giant cell tumor. Hematology\/Oncology and Stem Cell Therapy, 16(4), 307\u2013315. https:\/\/doi.org\/10.56875\/2589-0646.1032","journal-title":"Hematology\/Oncology and Stem Cell Therapy"},{"issue":"1","key":"10328_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51211-y","volume":"9","author":"FGM Verspoor","year":"2019","unstructured":"Verspoor, F. G. M., Mastboom, M. J. L., Hannink, G., Maki, R. G., Wagner, A., Bompas, E., et al. (2019). Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor. Scientific Reports, 9(1), Article 14551. https:\/\/doi.org\/10.1038\/s41598-019-51211-y","journal-title":"Scientific Reports"},{"issue":"6","key":"10328_CR87","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier, P. A., Gelderblom, H., Stacchiotti, S., Thomas, D., Maki, R. G., Kroep, J. R., et al. (2012). Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer, 118(6), 1649\u20131655. https:\/\/doi.org\/10.1002\/cncr.26409","journal-title":"Cancer"},{"key":"10328_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115756","volume":"229","author":"M van de Sande","year":"2025","unstructured":"van de Sande, M., Johnson, K., van Langevelde, K., Scharschmidt, T., Alani, L., Nguyen, D., et al. (2025). Pharmacokinetics and pharmacodynamics of an anti-CSF1 receptor antibody in the intra-articular treatment of tenosynovial giant cell tumor. European Journal of Cancer, 229, Article 115756. https:\/\/doi.org\/10.1016\/j.ejca.2025.115756","journal-title":"European Journal of Cancer"},{"issue":"18","key":"10328_CR89","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.Ccr-24-0103","volume":"30","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom, H., Razak, A. A., Taylor, M. H., Bauer, T. M., Wilky, B., Martin-Broto, J., et al. (2024). CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: A phase I study of vimseltinib. Clinical Cancer Research, 30(18), 3996\u20134004. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0103","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10328_CR90","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1158\/1535-7163.Mct-21-0361","volume":"20","author":"BD Smith","year":"2021","unstructured":"Smith, B. D., Kaufman, M. D., Wise, S. C., Ahn, Y. M., Caldwell, T. M., Leary, C. B., et al. (2021). Vimseltinib: A precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages. Molecular Cancer Therapeutics, 20(11), 2098\u20132109. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0361","journal-title":"Molecular Cancer Therapeutics"},{"issue":"10445","key":"10328_CR91","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","volume":"403","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom, H., Bhadri, V., Stacchiotti, S., Bauer, S., Wagner, A. J., van de Sande, M., et al. (2024). Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 403(10445), 2709\u20132719. https:\/\/doi.org\/10.1016\/S0140-6736(24)00885-7","journal-title":"Lancet"},{"issue":"1","key":"10328_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-3-8","volume":"3","author":"S Stacchiotti","year":"2013","unstructured":"Stacchiotti, S., Crippa, F., Messina, A., Pilotti, S., Gronchi, A., Blay, J. Y., et al. (2013). Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clinical Sarcoma Research, 3(1), Article 8. https:\/\/doi.org\/10.1186\/2045-3329-3-8","journal-title":"Clinical Sarcoma Research"},{"issue":"3","key":"10328_CR93","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","volume":"100","author":"A Galanis","year":"2015","unstructured":"Galanis, A., & Levis, M. (2015). Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica, 100(3), e77-79. https:\/\/doi.org\/10.3324\/haematol.2014.117028","journal-title":"Haematologica"},{"issue":"21","key":"10328_CR94","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1182\/blood.V120.21.1638.1638","volume":"120","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz, C. H., Younes, A., de Vos, S., Bociek, R. G., Gordon, L. I., Witzig, T. E., et al. (2012). CSF1R inhibition by PLX3397 in patients with relapsed or refractory Hodgkin lymphoma: Results from a phase 2 single agent clinical trial. Blood, 120(21), 1638\u20131638. https:\/\/doi.org\/10.1182\/blood.V120.21.1638.1638","journal-title":"Blood"},{"issue":"15_suppl","key":"10328_CR95","doi-asserted-by":"publisher","first-page":"10546","DOI":"10.1200\/JCO.2017.35.15_suppl.10546","volume":"35","author":"L Hittson","year":"2017","unstructured":"Hittson, L., Glod, J., Amaya, M., Derdak, J., Widemann, B. C., & Kaplan, R. N. (2017). Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN). Journal of Clinical Oncology, 35(15_suppl), 10546\u201310546. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.10546","journal-title":"Journal of Clinical Oncology"},{"key":"10328_CR96","unstructured":"ClinicalTrials.gov (2021). PLX3397 KIT in Acral aNd mucOsal Melanoma (PIANO). https:\/\/clinicaltrials.gov\/study\/NCT02071940. Accessed 1 Mar 2026."},{"key":"10328_CR97","unstructured":"ClinicalTrials.gov (2026). A study of PLX3397 in patients with unresectable or metastatic KIT-mutated melanoma. https:\/\/clinicaltrials.gov\/study\/NCT02975700. Accessed 1 Mar 2026."},{"key":"10328_CR98","unstructured":"ClinicalTrials.gov (2025). CGT9486 (formerly known as PLX9486) as a single agent and in combination with PLX3397 (Pexidartinib) or sunitinib in participants with advanced solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT02401815. Accessed 1 Mar 2026."},{"key":"10328_CR99","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.suronc.2020.08.030","volume":"35","author":"MJL Mastboom","year":"2020","unstructured":"Mastboom, M. J. L., Lips, W., van Langevelde, K., Mifsud, M., Ng, C., McCarthy, C. L., et al. (2020). The effect of imatinib mesylate in diffuse-type tenosynovial giant cell tumours on MR imaging and PET-CT. Surgical Oncology, 35, 261\u2013267. https:\/\/doi.org\/10.1016\/j.suronc.2020.08.030","journal-title":"Surgical Oncology"},{"issue":"22","key":"10328_CR100","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1158\/1078-0432.Ccr-22-1898","volume":"28","author":"DGP van IJzendoorn","year":"2022","unstructured":"van IJzendoorn, D. G. P., Matusiak, M., Charville, G. W., Spierenburg, G., Varma, S., Colburg, D. R. C., et al. (2022). Interactions in CSF1-driven tenosynovial giant cell tumors. Clinical Cancer Research, 28(22), 4934\u20134946. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1898","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10328_CR101","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10637-019-00745-z","volume":"38","author":"JH Lee","year":"2020","unstructured":"Lee, J. H., Chen, T. W., Hsu, C. H., Yen, Y. H., Yang, J. C., Cheng, A. L., et al. (2020). A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Investigational New Drugs, 38(1), 99\u2013110. https:\/\/doi.org\/10.1007\/s10637-019-00745-z","journal-title":"Investigational New Drugs"},{"key":"10328_CR102","unstructured":"ClinicalTrials.gov (2021). A study of pexidartinib in tenosynovial giant cell tumor in Japan. https:\/\/clinicaltrials.gov\/study\/NCT04703322?term=TGCT&intr=pexidartinib&rank=2. Accessed 1 Dec 2024."},{"key":"10328_CR103","unstructured":"ClinicalTrials.gov (2015). Phase I trial of TURALIO (Pexidartinib, PLX3397) in children and young adults with refractory leukemias and refractory solid tumors including neurofibromatosis type 1 (NF1) associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT). https:\/\/clinicaltrials.gov\/study\/NCT02390752?term=TGCT&intr=pexidartinib&rank=8. Accessed 1 Dec 2024."}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10328-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10328-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10328-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:40:22Z","timestamp":1775094022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10328-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":103,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["10328"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10328-z","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}